Brought to you by 
Bayer, Myriad Genetics sign gene discovery pact
02 Dec 1999
Executive Summary
Bayer Corp. has agreed to pay Myriad Genetics (genomics) as much as $71mm under the terms of a five-year R&D partnership to search for the genes linked to obesity, osteoporosis and asthma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer, Myriad Genetics sign gene discovery pact
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice